Last reviewed · How we verify
MT-601
At a glance
| Generic name | MT-601 |
|---|---|
| Sponsor | Marker Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (PHASE1)
- MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-601 CI brief — competitive landscape report
- MT-601 updates RSS · CI watch RSS
- Marker Therapeutics, Inc. portfolio CI